Clinical applicability of methylome sequencing in a pilot study of ischemic stroke individuals

Mark Ziemann, Harikrishnan Kaipananickal, Ishant Khurana, Antony Kaspi, Samuel T Keating, Deidre Anne De Silva, Kyaw Thu Moe, Assam El-Osta

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Despite recent progress in screening for genetic causes of cardiovascular disease using genome-wide association studies, identifying causative polymorphisms has not met initial expectations. This has led to interest in exploring the contribution of non-genetic factors in disease etiology. Elevated plasma homocysteine is an independent risk factor for cardiovascular disease but the mechanism for increased risk remains poorly understood. This study evaluates the clinical applicability of screening for genome-wide CpG methylation differences using methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq). Peripheral blood genomic DNA methylation in 8 Singaporean-Chinese ischemic stroke patients (4 male, 4 female) was profiled. Differential methylation of genes implicated in hyperhomocysteinemia was observed in males correlating with homocysteine; namely CBS (cystathionine-beta-synthase) and MTHFR (methylenetetrahydrofolate reductase). In females, hypomethylation of the LDLR (low density lipoprotein receptor) and CELSR1 (cadherin, EGF LAG seven-pass G-type receptor 1) genes were observed in the hypertensive group (2 normal and 2 hypertensive individuals). While the number of clinical samples analysed is small, the findings of this evaluation suggest that MBD-seq is a suitable and sufficiently sensitive technology to determine methylation variability. The results presented warrant an expanded case-control study to determine the pathophysiological implications of DNA methylation for hyper-homocysteinemia.
Original languageEnglish
Pages (from-to)11-22
Number of pages12
JournalMethods in Next Generation Sequencing
Volume2
Issue number1
DOIs
Publication statusPublished - Jan 2015

Cite this

Ziemann, Mark ; Kaipananickal, Harikrishnan ; Khurana, Ishant ; Kaspi, Antony ; Keating, Samuel T ; De Silva, Deidre Anne ; Moe, Kyaw Thu ; El-Osta, Assam. / Clinical applicability of methylome sequencing in a pilot study of ischemic stroke individuals. In: Methods in Next Generation Sequencing. 2015 ; Vol. 2, No. 1. pp. 11-22.
@article{84c3cdceedaa4760998b0e1fe961113d,
title = "Clinical applicability of methylome sequencing in a pilot study of ischemic stroke individuals",
abstract = "Despite recent progress in screening for genetic causes of cardiovascular disease using genome-wide association studies, identifying causative polymorphisms has not met initial expectations. This has led to interest in exploring the contribution of non-genetic factors in disease etiology. Elevated plasma homocysteine is an independent risk factor for cardiovascular disease but the mechanism for increased risk remains poorly understood. This study evaluates the clinical applicability of screening for genome-wide CpG methylation differences using methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq). Peripheral blood genomic DNA methylation in 8 Singaporean-Chinese ischemic stroke patients (4 male, 4 female) was profiled. Differential methylation of genes implicated in hyperhomocysteinemia was observed in males correlating with homocysteine; namely CBS (cystathionine-beta-synthase) and MTHFR (methylenetetrahydrofolate reductase). In females, hypomethylation of the LDLR (low density lipoprotein receptor) and CELSR1 (cadherin, EGF LAG seven-pass G-type receptor 1) genes were observed in the hypertensive group (2 normal and 2 hypertensive individuals). While the number of clinical samples analysed is small, the findings of this evaluation suggest that MBD-seq is a suitable and sufficiently sensitive technology to determine methylation variability. The results presented warrant an expanded case-control study to determine the pathophysiological implications of DNA methylation for hyper-homocysteinemia.",
author = "Mark Ziemann and Harikrishnan Kaipananickal and Ishant Khurana and Antony Kaspi and Keating, {Samuel T} and {De Silva}, {Deidre Anne} and Moe, {Kyaw Thu} and Assam El-Osta",
year = "2015",
month = "1",
doi = "10.1515/mngs-2015-0002",
language = "English",
volume = "2",
pages = "11--22",
journal = "Methods in Next Generation Sequencing",
issn = "2084-7173",
publisher = "Walter de Gruyter",
number = "1",

}

Clinical applicability of methylome sequencing in a pilot study of ischemic stroke individuals. / Ziemann, Mark; Kaipananickal, Harikrishnan; Khurana, Ishant; Kaspi, Antony; Keating, Samuel T; De Silva, Deidre Anne; Moe, Kyaw Thu; El-Osta, Assam.

In: Methods in Next Generation Sequencing, Vol. 2, No. 1, 01.2015, p. 11-22.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Clinical applicability of methylome sequencing in a pilot study of ischemic stroke individuals

AU - Ziemann, Mark

AU - Kaipananickal, Harikrishnan

AU - Khurana, Ishant

AU - Kaspi, Antony

AU - Keating, Samuel T

AU - De Silva, Deidre Anne

AU - Moe, Kyaw Thu

AU - El-Osta, Assam

PY - 2015/1

Y1 - 2015/1

N2 - Despite recent progress in screening for genetic causes of cardiovascular disease using genome-wide association studies, identifying causative polymorphisms has not met initial expectations. This has led to interest in exploring the contribution of non-genetic factors in disease etiology. Elevated plasma homocysteine is an independent risk factor for cardiovascular disease but the mechanism for increased risk remains poorly understood. This study evaluates the clinical applicability of screening for genome-wide CpG methylation differences using methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq). Peripheral blood genomic DNA methylation in 8 Singaporean-Chinese ischemic stroke patients (4 male, 4 female) was profiled. Differential methylation of genes implicated in hyperhomocysteinemia was observed in males correlating with homocysteine; namely CBS (cystathionine-beta-synthase) and MTHFR (methylenetetrahydrofolate reductase). In females, hypomethylation of the LDLR (low density lipoprotein receptor) and CELSR1 (cadherin, EGF LAG seven-pass G-type receptor 1) genes were observed in the hypertensive group (2 normal and 2 hypertensive individuals). While the number of clinical samples analysed is small, the findings of this evaluation suggest that MBD-seq is a suitable and sufficiently sensitive technology to determine methylation variability. The results presented warrant an expanded case-control study to determine the pathophysiological implications of DNA methylation for hyper-homocysteinemia.

AB - Despite recent progress in screening for genetic causes of cardiovascular disease using genome-wide association studies, identifying causative polymorphisms has not met initial expectations. This has led to interest in exploring the contribution of non-genetic factors in disease etiology. Elevated plasma homocysteine is an independent risk factor for cardiovascular disease but the mechanism for increased risk remains poorly understood. This study evaluates the clinical applicability of screening for genome-wide CpG methylation differences using methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq). Peripheral blood genomic DNA methylation in 8 Singaporean-Chinese ischemic stroke patients (4 male, 4 female) was profiled. Differential methylation of genes implicated in hyperhomocysteinemia was observed in males correlating with homocysteine; namely CBS (cystathionine-beta-synthase) and MTHFR (methylenetetrahydrofolate reductase). In females, hypomethylation of the LDLR (low density lipoprotein receptor) and CELSR1 (cadherin, EGF LAG seven-pass G-type receptor 1) genes were observed in the hypertensive group (2 normal and 2 hypertensive individuals). While the number of clinical samples analysed is small, the findings of this evaluation suggest that MBD-seq is a suitable and sufficiently sensitive technology to determine methylation variability. The results presented warrant an expanded case-control study to determine the pathophysiological implications of DNA methylation for hyper-homocysteinemia.

U2 - 10.1515/mngs-2015-0002

DO - 10.1515/mngs-2015-0002

M3 - Article

VL - 2

SP - 11

EP - 22

JO - Methods in Next Generation Sequencing

JF - Methods in Next Generation Sequencing

SN - 2084-7173

IS - 1

ER -